colon cancer
Conditions
Interventions
FA+FA group:Flurbiprofen axetil 50mg i.v. before induction
FA+FA group:PCA with Sufentanil 1µg/kg +Flurbiprofen axetil 300mg+Tropisetron 10mg
Sponsors
Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. patients underwent elective colon cancer radical surgery; 2. aged 18-75 year; 3. ASA physical status from I to II.
Exclusion criteria
Exclusion criteria: 1. patients with the history of Gastrointestinal ulcer; 2. TNM stage greater than or equal to III; 3. patients with bleeding tendency or abnormal hematologic System; 4. Patients with heart, liver and kidney dysfunction; 5. patients with high blood pressure; 6. patients with asthma; 7. patients using quinolone antibiotics recently; 8. Patients participated in other clinical trials in the past three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in perioperative immune-related cells, including: number of CD4+, CD8+ and NK cells, CD4+/CD8+ ratio; | — |
Secondary
| Measure | Time frame |
|---|---|
| Plasma IL-2, IL-6, IL-10, TNF-a factor levels;total intraoperative use of propofol and remifentanil;VAS score 48h after operation,the number of times the analgesic pump was pressed and the total amount of drug used.;Survival at 120 days and recurrence at 1 year;Hemodynamic changes at each time point during the operation;Consumption of analgesics within 48 hours after surgery;Postoperative recovery time of gastrointestinal function (first exhaust time, defecation time and fluid intake time);Incidence of postoperative adverse reactions (pruritus, nausea, vomiting, drowsiness, fever, chills, etc.); | — |
Countries
China
Contacts
Public ContactSu Liu
Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed